Close
  • Home

Archive - August 2020

ADC Digest - August 2020

ADC Digest - August 2020

Antibody–drug conjugates (ADCs)

ADC ‘s are the next generation “targetted” missiles being built in different shapes and forms to attack the enemy in a multitude of ways. What is an ADC – its is a monoclonal antibody tethered to a payload via a chemical linker. They lack the complexity of CAR-Ts, but have their own “improvement” areas. It will be a new weapon in our armamentarium. In the span of 2 weeks we saw both GlaxoSmithKline and AstraZeneca moving ahead with their ADC programs. Read more, tile wise below

Regulatory
U.S. Food and Drug Administration grants Breakthrough Therapy Designation to Multitude Therapeutics’ AMT-253
7 August 2026
Regulatory
Multitude Therapeutics’ AMT-676 receives Breakthrough Therapy Designation from China’s CDE
7 August 2026
Regulatory
TQB2102 receives BTD from the CDE for patients with unresectable or metastatic HER2-low Breast cancer
7 August 2026
Regulatory
U.S. FDA grants Orphan Drug Designation to Zai Lab’s DLL3-targeting ADC Zocilurtatug pelitecan for the...
7 August 2026
Regulatory
DualityBio and BioNTech’s B7-H3 ADC DB-1311 granted China NMPA BTD for metastatic castration-resistant Prostate cancer
31 July 2026
Regulatory
Gilead announces CHMP recommendation for Trodelvy + Keytruda in 1L PD-(L)1+ mTNBC
31 July 2026

Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id